OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice

OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice

PurposeThis study aimed to investigate the effect of OCT4&SOX2 specific cytotoxic T lymphocytes (CTLs) plus programmed cell death protein-1 (PD-1) inhibitor (nivolumab) on treating breast cancer stem-like cells (BCSCs) in vitro and drug-resistance breast cancer (DRBC) mice in vivo.MethodsIn...

Full description

Bibliographic Details
Main Authors: Wei Peng, Liang Chang, Wenqiang Li, Yanan Liu, Min Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
OCT4 and SOX2
cytotoxic T lymphocytes
PD-1 inhibitor
breast cancer stem-like cells
drug-resistance breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.781093/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.781093/full

Similar Items